Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Are The Future Growth Projections For The Growth Hormone Deficiency Market Size?

There has been a robust expansion in the size of the market for growth hormone deficiency in the past few years. It is projected to climb from $4.06 billion in 2024 to $4.3 billion in 2025, with a compound annual growth rate (CAGR) of 5.8%. The previous growth can be ascribed to the surge in strategic initiatives, an uptick in brain tumor cases, escalating demand for hormone treatments, a rise in the aging population, and increased government healthcare funding.

The market size of growth hormone deficiency is predicted to experience robust expansion in the coming years, reaching $5.38 billion in 2029 with a compound annual growth rate (CAGR) of 5.7%. Several factors contributing to this growth during the forecasted period include a surge in genetic disorders, heightened strategic efforts, enhanced research and development, a rise in the incidence of Gh disease, and an increase in clinical trials. Foreseen trends during this period encompass technological progress, growing treatment alternatives, improvements in diagnostic methods, recent developments, and progress in biotechnology.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21197&type=smp

Which Demand Drivers Are Strengthening The Growth Hormone Deficiency Market?

The rise in genetic disorders is anticipated to boost the growth hormone deficiency market’s expansion. Genetic disorders are health issues borne from DNA abnormalities or mutations, which could either be inherited or suddenly appear. The increased occurrence of these disorders can be attributed to improved diagnosis techniques, heightened awareness, ageing mothers, environmental factors causing mutations, population increase, and better survival rates for affected people. Growth hormone deficiency is utilized to handle growth complications related to some genetic conditions. For example, a report in December 2022 from the Department of Health & Social Care (DHSC) in the UK revealed that about 33,000 whole genome equivalents were sequenced in October 2022, yielding an average diagnostic result of 32%, which increased to 61% in particular conditions. Consequently, the rising incidence of genetic disorders is fueling the expansion of the growth hormone deficiency market.

What Segmentation Insights Are Provided In The Growth Hormone Deficiency Market Research?

The growth hormone deficiencymarket covered in this report is segmented –

1) By Type: Pediatric Growth Hormone Deficiency; Adult Growth Hormone Deficiency

2) By Treatment: Pharmacological Therapy; Recombinant Human Growth Hormone; Human Pituitary Gland Extracts; Surgery

3) By Route Of Administration: Intravenous; Intramuscular; Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy

5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users

Subsegments:

1) By Pediatric Growth Hormone Deficiency: Idiopathic Growth Hormone Deficiency; Genetic Growth Hormone Deficiency; Acquired Growth Hormone Deficiency

2) By Adult Growth Hormone Deficiency: Primary Growth Hormone Deficiency; Secondary Growth Hormone Deficiency

Which Notable Trends Are Transforming The Growth Hormone Deficiency Market Outlook?

In the growth hormone deficiency market, companies are creating innovative therapies like unmodified somatropin to improve treatment for pediatric patients. Unmodified somatropin is traditionally used in daily GHD treatment, now reformulated for weekly use with Skytrofa. In September 2023, Denmark-based Ascendis Pharma A/S launched SKYTROFA (lonapegsomatropin), the first FDA-approved once-weekly treatment for pediatric GHD. It offers improved convenience, better patient compliance, and potentially enhanced outcomes compared to daily injections, marking a significant milestone in pediatric endocrine care.

Which Firms Are Driving Innovation Within The Growth Hormone Deficiency Market?

Major companies operating in the growth hormone deficiency market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Eli Lilly and Company, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Genentech Inc., Ipsen Biopharmaceuticals Inc., Opko Health Inc., JCR Pharmaceuticals Co. Ltd., Ferring Pharmaceuticals Inc., Ascendis Pharma A/S, Rani Therapeutics Inc., AnkeBio Co. Ltd., Aeterna Zentaris Inc., Zhongshan Sinobioway Hygene Biomedicine Co. Ltd., Versartis Inc., I-Mab Biopharma Co. Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/growth-hormone-deficiency-global-market-report

Which Regional Markets Are Emerging As Key Hubs For The Growth Hormone Deficiency Market?

North America was the largest region in the growth hormone deficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the growth hormone deficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21197&type=smp

Browse Through More Reports Similar to the Global Growth Hormone Deficiency Market 2025, By The Business Research Company

Biosimilar Growth Hormone Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report

Parathyroid Hormones Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report

Biosimilar Hormone Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model